Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

Diabetologia

Volumn 58, Issue 9, 2015, Pages 2020-2026

  Kothny, Wolfgang ^a   Lukashevich, Valentina ^a   Foley, James E ^a   Rendell, Marc S ^b,c   Schweizer, Anja ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Association of Diabetes Investigators   (United States)

Author keywords

Renal impairment; Sitagliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; SITAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; ASTHENIA; BLURRED VISION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; TREMOR; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; BRAZIL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; KIDNEY DISEASES; MIDDLE AGED; UNITED STATES;

ADAMANTANE; AGED; BLOOD GLUCOSE; BRAZIL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; SITAGLIPTIN PHOSPHATE; UNITED STATES;

EID: 84938747822     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3655-z     Document Type: Article

References (24)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532–2539
2. Villar E, Zaoui P (2010) Diabetes and chronic kidney disease: lessons from renal epidemiology. Nephrol Ther 6:585–590
3. Lubowsky ND, Siegel R, Pittas AG (2007) Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 50:865–879
4. Ritz E (2011) Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 34(Suppl 2):S330–S334
5. Gerich JE, Meyer C, Woerle HJ, Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382–391
6. Arem R (1989) Hypoglycemia associated with renal failure. Endocrinol Metab Clin N Am 18:103–121
7. Scheen AJ (2015) Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54:1–21
8. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13:775–783
9. Davis JA, Singh S, Sethi S et al (2010) Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. Indian J Pharm 42:229–233
10. Dejager S, Schweizer A (2012) Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract 40:7–21
11. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomised placebo-controlled trial. Diabetes Obes Metab 13:947–954
12. Keating GM (2014) Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 74:587–610
13. Herman GA, Stevens C, Van Dyck K et al (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675–688
14. Vincent SH, Reed JR, Bergman AJ et al (2007) Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–538
15. Bergman AJ, Cote J, Yi B et al (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862–1864
16. Chan JC, Scott R, Arjona Ferreira JC et al (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10:545–555
17. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G (2010) Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 24:79–83
18. Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35:2076–2082
19. Ito M, Abe M, Okada K et al (2011) The dipeptidyl peptidase-4 [DPP-4] inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 58:979–987
20. Kothny W, Shao Q, Groop PH, Lukashevich V (2012) One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 14:1032–1039
21. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W (2010) An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 12:495–509
22. Nowicki M, Rychlik I, Haller H et al (2011) Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 13:523–532
23. Nowicki M, Rychlik I, Haller H et al (2011) Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 65:1230–1239
24. McGill JB, Sloan L, Newman J et al (2013) Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomised, double-blind, placebo-controlled study. Diabetes Care 36:237–244